Privileged scaffolds targeting reverse-turn and helix recognition

Washington University, Center for Computational Biology and Department of Biochemistry and Molecular Biophysics, St. Louis, MO 63110, USA.
Expert Opinion on Therapeutic Targets (Impact Factor: 5.14). 02/2008; 12(1):101-14. DOI: 10.1517/14728222.12.1.101
Source: PubMed


Protein-protein interactions dominate molecular recognition in biologic systems. One major challenge for drug discovery arises from the very large surfaces that are characteristic of many protein-protein interactions.
To identify 'drug-like' small molecule leads capable of modulating protein-protein interactions based on common protein-recognition motifs, such as alpha-helices, beta-strands, reverse-turns and polyproline motifs for example.
Many proteins/peptides are unstructured under physiologic conditions and only fold into ordered structures on binding to their cellular targets. Therefore, preorganization of an inhibitor into its protein-bound conformation reduces the entropy of binding and enhances the relative affinity of the inhibitor. Accordingly, this review describes a general strategy to address the challenge based on the 'privileged structure hypothesis' [Che, PhD thesis, Washington University, 2003] that chemical templates capable of mimicking surfaces of protein-recognition motifs are potential privileged scaffolds as small-molecule inhibitors of protein-protein interactions. The authors highlight recent advances in the design of privileged scaffolds targeting reverse-turn and helical recognition.
Privileged scaffolds targeting common protein-recognition motifs are useful to help elucidate the receptor-bound conformation and to provide non-peptidic, bioavailable substructures suitable for optimization to modulate protein-protein interactions.

Download full-text


Available from: Ye Che, Jan 02, 2015
  • Source
    • "Although this theory cannot be treated as a rule any longer and many exceptions can be listed, nevertheless it has become the foundation of molecular design and the concept of pharmacophores. In 2000, the concept of privileged motifs, which were formerly known as molecular moieties, which are able to construct effective ligands for diverse receptors, was further developed [64] [65] [66] [67] [68] [69] [70] [71]. The last decade has made this idea more popular and numerous moieties have been claimed to be privileged: benzazepinone [65], diphenylmethane, piperidine, biphenyltetrazole [65], indole [65] [72], biphenyl [65] [73], spiroindoline sulfonamide [65] [74], spiroindanyl piperidine [74], dihydropyridine [75], and benzopyran [76] [77]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV integrase became an important target for drug development more than twenty years ago. However, progress has been hampered by the lack of assays suitable for high throughput screening, a reliable crystal structure or pharmacophore. Thus, a real breakthrough was only observed in 2007 with the introduction of the first integrase inhibitor, raltegravir, into treatment. To date, the armament of integrase inhibitors is broad and covers several drugs from different classes that are under clinical trials. Among them, quinoline-based compounds and analogues occupy an important place. This review is focused on those compounds that have a quinoline scaffold and attempts to answer the question of whether quinoline is privileged for these activities. In fact, quinoline has been claimed as a privileged structure several times for different fields of activities. A closer look at its structural features may reveal the prerequisites responsible for the popularity of quinoline-based inhibitors of HIV integrase.
    Full-text · Article · Oct 2012 · Current pharmaceutical design
  • Source
    • "Later this definition was updated by Patchett and Nargund [3]. Since then, several reviews deal with the concept of privileged motifs [4] [5] [6] [7] [8] [9] and numerous molecular fragments have been described as privileged, e.g. benzazepinone [3], diphenylmethane [3], benzylpiperidine [3], biphenyltetrazole [3], indole [3] [10], biphenyl [3] [11], spiroindoline sulfonamide [3] [12], spiroindanyl piperidine [12], 1,4-dihydropyridine [13], 2,6-dichloro- 9-thiabicyclo[3.3.1]nonane "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug design is a complex issue that still lack general approach with proven reliability. Combinatorial chemistry and HTS techniques did not appear to be effort-effective. As an alternative we have the fragment based design and more recently so called the privileged structures approach. We believe that some structural subunits are especially effective in design of bioeffectors. However it is not clear what makes one molecular scaffold more privileged than another. Overall frequency of appearance of molecular scaffold in bioactive compounds or natural substances may be used as a good factor of qualitative discriminator of privileged structures. According this, the quinoline scaffold, due to its frequent appearance in bioactive substances can be regarded as a privileged structure. It is abundant in number of natural compounds such as alkaloids: quinine, camptothecin or cinchonidine. In synthetic medicinal chemistry the quinoline motif is widely exploited revealing a spectrum of activity covering anticancer, antifungal, antibacterial and antiprotozoic effects. In fact, introducing chloroquine into treatment of malaria more than 60 years ago triggered a new era of quickly developing antimicrobial drugs through nalidixic acid and fluoroquinolones. In this review we wish to explore antimicrobial quinolines as an important class of drugs from both natural and synthetic sources.
    Full-text · Chapter · Jan 2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: 5-Oxobenzo[e][1,4]diazepine-3-carboxamides were synthesized by sequential Ugi reaction-Staudinger/aza-Wittig cyclization. The pseudopeptidic backbone of the new benzodiazepine derivatives superimposed well with type I, I', II, and II' beta-turn motifs. The intermediate Ugi adducts were characterized as two conformers of the enol form by the correlation between (1)H NMR spectra and X-ray diffraction structures of model compounds.
    No preview · Article · Mar 2009 · The Journal of Organic Chemistry
Show more